Network Group BayHelix Links Life Sciences Leaders To Blaze New Trail In China – An Interview With PharmAsia News (Part 2 of 2)
BayHelix is a non-profit, invitation-only organization for ethnic Chinese leaders in the global life sciences arena. Created in the San Francisco Bay Area in 2001, BayHelix has since become a bridge linking 300-plus Chinese business, law and science professionals in the health care industry across the U.S., Canada and Greater China. Recently the chairman of BayHelix, James Zhu, managing partner of Perkins Coie's Beijing Office, and the group's two co-founders, Jonathan Wang, OrbiMed's managing director in Asia, and Steve Yang, vice president, Head of Asia R&D at Pfizer, sat down with PharmAsia News' Shanghai Bureau to talk about the founding and the future of BayHelix as well as the challenges and opportunities in China's life sciences sector.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
- • By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
- • By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
- • By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
- Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.





